Incidence history of west Nile virus in Africa and middle east, with an emphasis on Egypt: a review

Abstract

Importance: Since its initial isolation in Uganda in 1937 and its introduction in Egypt in 1950 through the present, West Nile virus (WNV) have had a significant global public health impact during the last decades due to their resurgence and dynamic epidemiologic features in human and animals, and its considered one of the largest arboviral neuroinvasive disease recorded in the world.

Objective: To review the incidence of West Nile virus in both animals and human, with an emphasis on Egypt, to follow the preventive measures to reduce the public health impact of WNV in areas with the potential for transmission.

Background: WNV has a history of irregular but recurrent epizootics in countries of Africa, Middle East and Central, Eastern and parts of southern Europe. WNV is an enveloped virus of the genus Flavivirus, is naturally maintained in an enzootic cycle between birds and mosquitoes, with occasional epizootic spillover causing sporadic cases and outbreaks of human and equine. It has recently gained considerable attention as re-emerging infections in a global scale. Environmental factors (heavy rains followed by floods, irrigation, high temperature, or mass breeding of mosquitoes) that enhance population densities of vector mosquitoes could increase the incidence of WNV infection. The disease gets its name from the West Nile District of Uganda where it was first recognized in humans in 1937. The first cases of WNV in horses were recognized in France and Egypt in the 1960’s. Since WNV is a biosafety level 3 agent, techniques that involve cell culture are restricted to laboratories with this level of biosafety, such as reference laboratories. Nevertheless, outbreaks of WNV remain unpredictable. Further coordinated studies are needed for a better understanding of the epidemiology of the virus.

Conclusion: In order to fully understand the impact of WNV and/or other flavivirus infections in Egypt, epidemiology and ecological features of these agents need to be established. West Nile virus has and will remain a formidable clinical and public health problem for years to come.

Keywords: west Nile virus, incidence, bird migration, neurological disease, Egypt

Abbreviations: WNV, west nile virus; PFU, plaque forming units; SLEV, saint louis encephalitis virus; JEV, japanese encephalitis virus; CDC, centers for disease control and prevention

Introduction

Since the West Nile virus (WNV) strain (B956) was isolated in 1937 from a clinical case was suffered from fever in the West Nile district of Uganda, WNV start to appear again in 1950s causing different infrequent outbreaks in different continent of the world including Egypt, Israel, France and India.1,6 In the past 78 years since its discovery, the disease has continued to increase in vast areas of the world to consider the main cause of viral encephalitis in the world. WNV is an emerging zoonotic arbovirus widely distributed throughout the world with both considerable impacts on public and animal health.1 The virus maintained in enzootic cycle involving mosquito’s vector and certain birds as reservoir hosts (Figure 1). There are many vertebrate hosts other than birds such as reptiles, amphibians, and mammals are susceptible to WNV infection.6 Although, humans and horses (incidental hosts) are not able to develop sufficient viremia to infect mosquito, and do not participate in the WNV lifecycle, it may undergo severe signs or death from infection. The virus was replicates in a wide range of mosquitoes and transmitted exclusively among avian species.2 Culex mosquitoes are infected during sucking viremic blood (approximately 104-105PFU/mL) Numerous reports have suggested that WNV may persist in the organs of birds in such a way as to permit retransmission to vector mosquitoes after the period of initial viremia.9

WNV history in Africa and Middle East

In 1937-1940, a serosurvey was conducted in Uganda, Sudan, Congo, and Kenya to compare the neutralizing titers for WNV, SLEV (Saint Louis encephalitis virus) and JEV (Japanese encephalitis virus). This study revealed widespread seropositivity of WNV over 50%.10 In 1951 and 1955, the samples collected from patients in western Nigeria showing seropositivity for WNV.11 In 1954, seropositivity to WNV was demonstrated in animals, humans, monkeys, and birds in South Africa.12 WNV was isolated for first time during outbreak near Haifa in Israel from a febrile child in 1951.13 In 1952 and 1953, subsequent WNV outbreaks occurring mainly in human in Israel and the virus was isolated from human and chickens.14-16 In 1980 and 2000, several WNV outbreaks attacked Israel with around 400 serologically
confirmed cases and around 35 deaths. Since that time, Israel has the experience to regulate and predict the annual summertime outbreaks, similar to those observed in the United States. WNV was reported in Turkey in the 1970s and 2000s, followed by an epidemic reported in 2010-11, including Turkey and area of Mediterranean. In Iran, there were many WNV cases were recorded in the 1970s, 2008s, and 2009s of patients suffered from fever, and some nervous signs, these cases were identified by RT-PCR and presence of specific IgG in their blood.

In 2008-2009, a study was conducted on horses in Iran to identify WNV antibodies, the results revealed the highest activity of virus in western and southern provinces with seroprevalences up to 88% in some areas. Although, no human cases have been reported, animal infections with WNV were recorded in Jordan and Lebanon. In the late 20th and early 21st century, outbreaks of WNV continued to infect humans and/or horses in different localities in northern and sub-Saharan Africa (Figure 2) with active transmission in Morocco in 2010 and Tunisia in 2012 and ongoing sporadic transmissions in Algeria and Egypt. In 2006, recent reports have indicated ongoing WNV transmission in Guinea; Ghana in 2009, and fatality cases in Gabon in 2009. In 2009, seroconversion of sentinel chickens was observed in Senegal. In 2010, the first case of lineage 1 WNV was recorded in South Africa causing death of a pregnant mare. In 2010-2011, human and mosquitoes positive for WNV lineage 2 were reported in eastern Africa (Djibouti).

History of WNV in Egypt

WNV was first isolated in Egypt in 1950 in north of Cairo, where serosurveys was conducted of 251 individuals; mostly children showed that 22% of children and 61% of adults had antibodies to WNV. There are several large outbreaks were recognized in Egypt between 1951 and 1954, which led to a further understanding of the epidemiology of WNV. A study conducted in the Alexandria Fever Hospital in 1968 revealed that WNV infection was the etiology in 14.6% of the children admitted to the hospital with a febrile illness. In 1989, a seroprevalence study conducted in the Nile Delta showed only 3% prevalence of WNV in school children aged 8-14 years. In 1999, a preliminary serological study demonstrated the WNV was widely distributed in Egypt (NAMRU-3, unpublished data). Around 75% of the human infections with WNV are mostly asymptomatic, and less than 1% of infections progress to severe disease varies from flu-like to severe neurological symptoms. WNV infection causing morbidity and mortality in birds. In Egypt, prior to 1998, the only evidence for virulence of WNV in naturally infected bird was the isolation of the virus from pigeon.

Figure 1 Transmission cycle of WNV: the mosquito (Vector) especially Culex species” bite an infected bird (Amplifying host), the virus enters the mosquito’s blood stream and eventually moves into its salivary glands. The infected mosquito bite an animal or a human (Incidental Host) the virus is passed into the host’s bloodstream, where it may cause serious illness.

Figure 2 Geographical distribution of WNV in Africa and Middle East according to Centers for Disease Control and Prevention (CDC) reports, modified from www.mdpi.com.

Conclusion

Since its isolation in Africa in 1937, WNV has considered one of the most prevalent causes of arboviral neuro invasive disease in the world. Recent serious outbreaks of WNV in Africa and Middle East prove the risk of disease transmission with mosquitoes, the need to understand the epidemiology in endemic areas and the need for continues investigation and preventative measures. Few data exist regarding long-term sequelae from WNV infection, the risk of virus transmission associated with blood transfusion, potential therapeutic interferences, and vaccine possibilities. Physicians engaged in diagnosing and reporting WNV infection may greatly enhance knowledge of this emerging infectious disease.

Acknowledgements

None.

Conflict of interest

Author declares that there is no conflict of interest.

References

1. Smithburn KC, Hughes TP, Burke AW, et al. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg. 1940;20(4):471–492.

Citation: Sayed-Ahmed M. Incidence history of west Nile virus in Africa and middle east, with an emphasis on Egypt: a review. J Dairy Vet Anim Res. 2016;3(3):101–104. DOI: 10.15406/jdvar.2016.03.00080
2. Van der Meulen KM, Pensaert MB, Nauwynck HJ. West Nile virus in the vertebrate world. *Arch Virol.* 2005;150(4):637–657.

3. Taylor RM, Work TH, Hurlbut HS, et al. A study of the ecology of West Nile virus in Egypt. *Am J Trop Med Hyg.* 1956;5(4):579–620.

4. Southam CM, Moore AE. Induced virus infections in man by the Egypt isolates of West Nile virus. *Am J Trop Med Hyg.* 1954;3(1):19–50.

5. Southam CM, Moore AE. West Nile, Ilheus, and Bunyamwera virus infections in man. *Am J Trop Med Hyg.* 1951;36(6):724–741.

6. Mohammad YS, Gresikova M, Adamyova K, et al. Studies on arboviruses in Egypt. II. Contribution of arboviruses to the aetiology of undiagnosed fever among children. *J Hyg (Lond).* 1970;68(3):491–495.

7. Beck C, Irímez-Clavero MA, Leblond A, et al. Flaviviruses in Europe: complex circulation patterns and their consequences for the diagnosis and control of west Nile disease. *Int J Environ Res Public Health.* 2013;10(11):6049–6083.

8. McLean RG, Ubico SR, Bourne D, et al. West Nile virus in livestock and wildlife. *Curr Top Microbiol Immunol.* 2002;267:271–308.

9. Komar N, Langevin S, Hinten S, et al. Experimental infection of North American birds with the New York 1999 strain of West Nile virus. *Emerg Infect Dis.* 2003;9(3):311–322.

10. Smithburn KC, Jacobs RH. Neutralization-tests against neurotropic viruses with sera collected in central Africa. *J Immunol.* 1942;44(1):9–23.

11. Macnamara FN, Horn DW, Porterfield JS. Yellow fever and other arthropod-borne viruses: a consideration of two serological surveys made in South Western Nigeria. *Trans R Soc Trop Med Hyg.* 1959;53(2):202–212.

12. Kokernot RH, Smithburn KC, Weinbren MP. Neutralizing antibodies to arthropod-borne viruses in human beings and animals in the Union of South Africa. *J Immunol.* 1956;77(5):313–332.

13. Bernkopf H, Levine S, Nerson R. Isolation of West Nile virus in Israel. *J Inf Dis.* 1953;93(3):207–218.

14. Goldblum N, Sterk VV, Paderski B. West Nile fever: The clinical features of the disease and the isolation of west Nile virus from the blood of nine human cases. *Goldblum N, Sterk VV, Paderski B. West Nile fever: The clinical features of the disease and the isolation of west Nile virus from the blood of nine human cases. *Emerg Infect Dis.* 2000;6(4):358–362.

15. Kopel E, Amitai Z, Bin H, et al. Surveillance of West Nile virus disease, Israel, 2000: epidemiologic aspects. *Epidemiol Infect.* 2001;126(5):197–204.

16. Weinberger M, Pitlik SD, Gandacu D, et al. West Nile fever outbreak, Israel, 2000: epidemiologic aspects. *Emerg Infect Dis.* 2001;7(4):686–691.

17. Kopel E, Amitai Z, Bin H, et al. Surveillance of West Nile virus disease, Tel Aviv district, Israel, 2005 to 2010. *Euro surrivel.* 2011;16(25):1–7.

18. Anis E, Grotto I, Mendelson E, et al. West Nile fever in Israel: the reemergence of an endemic disease. *J Infect.* 2014;68(2):170–175.

19. Ergunay K, Ozer N, Us D, et al. Seroprevalence of West Nile virus and tick-borne encephalitis virus in Southeastern Turkey: first evidence for tick-borne encephalitis virus infections. *Vector-Borne and Zoonotic Dis.* 2007;7(2):157–161.

20. Meco O. West Nile arbovirus antibodies with hemagglutination inhibition (HI) in residents of Southeast Anatolia. *Microbiol Bull.* 1977;11(1):3–17.

21. Ozer N, Ergunay K, Simsek F, et al. West Nile virus studies in the Sancılarfa Province of Turkey. *J Vector Ecol.* 2007;32(2):202–206.

22. Ozkul A, Yildirim Y, Pinar D, et al. Serological evidence of West Nile Virus (WNV) in mammalian species in Turkey. *Epidemiol Infect.* 2006;134(4):826–829.

23. Radda A. Studies on the activity and ecology of arboviruses in Turkey. Zentralblatt fur Bakteriologie, Parakstenkunde, Infektionskrankheiten und Hygiene. Zentralbl Bakteriol Orig A. 1973;225(1):19–26.

24. Kalaycioglu H, Korakuoglu G, Ozkul A, et al. Emergence of West Nile virus infections in humans in Turkey 2010 to 2011. *Euro Surveill.* 2012;17(21):20182.

25. Naficy K, Saidi S. Serological survey on viral antibodies in Iran. *Trop Geogr Med.* 1970;22(2):183–188.

26. Chinkar S, Javadi A, Ataei B, et al. Detection of West Nile virus genome and specific antibodies in Iranian encephalitis patients. *Epidemiol Infect.* 2012;140(8):1525–1529.

27. Ahmadnejad F, Otarod V, Fallah MH, et al. Spread of West Nile virus in Iran: a cross-sectional serosurvey in equines, 2008–2009. *Epidemiol Infect.* 2011;139(10):1587–1593.

28. Batieha A, Saliba EK, Graham R, et al. Seroprevalence of West Nile, Rift Valley, and sandfly arboviruses in Hashimiah, Jordan. *Emerg Infect Dis.* 2000;6(4):358–362.

29. Gallian P, de Micco P, Ghorra P. Seroprevalence of West Nile virus in blood donors at Hotel Dieu de France, Beirut, Lebanon, *Transfusion.* 2010;50(5):1156–1158.

30. Garabedian GA, Matossian RM, Musalli MN. Serologic evidence of arbovirus infection in Lebanon. *J Med Libanais.* 1971;24(4):339–350.

31. Abutarbush SM, Al-Majali AM. West Nile virus infection in horses in Jordan: clinical cases, seroprevalence and risk factors. *Transbound Emerg Dis.* 2014;61(Suppl 1):1–6.

32. Cabre O, Grandadam M, Marié JL, et al. West Nile virus in horses, sub-Saharan Africa. *Emerg Infect Dis.* 2006;12(12):1958–1960.

33. Kading RC, Borland EM, Cranfield M, et al. Prevalence of antibodies to alphaherpesviruses and flaviviruses in free-ranging game animals and nonhuman primates in the greater Congo basin. *J Wildlife Dis.* 2013;49(3):587–599.

34. Sghairer W, Bahri O, Kedous E, et al. Retrospective study of viral causes of central nervous system infections in Tunisia (2003–2009). *Med et Sante Trop.* 2012;22(4):373–378.

35. Morrill JC, Johnson BK, Hyams C, et al. Serological evidence of arboviral infections among humans of coastal Kenya. *J Trop Med Hyg.* 1991;94(3):166–168.

36. European Centre for Disease Prevention and Control. Historical data. 2013.

37. Hassine TB, Hammani S, Elghoul H, et al. Detection of circulation of West Nile virus in equine in the North-west of Tunisia. *Bull Soc Pathol Exot.* 2011;104(4):266–271.

38. El Rhaffouli H, Lahlou-Amine I, Loutfi C, et al. Serologic evidence of West Nile virus infection in Morocco. *Exot Med Sante Trop.* 2011;104(4):266–271.

39. El Harrak M, Slimallah M, Lahlou I, et al. Serologic evidence of West Nile virus infection among humans, sub-Saharan Africa. *Emerg Infect Dis.* 2006;12(12):1958–1960.

40. Gabriel M, Emmerich P, Frank C, et al. Increase in West Nile virus infections imported to Germany in 2012. *J Clin Virol.* 2013;58(3):587–589.

41. Soliman A, Mohareb E, Salaman D, et al. Studies on West Nile virus infection in Egypt. *J Infect Public Health.* 2010;3(2):54–59.

42. Jentes ES, Robinson J, Johnson BW, et al. Acute arboviral infections in children. *J Clin Virol.* 2013;58(3):587–589.

43. Wang W, Sarkodie F, Danso K, et al. Seroprevalence of West Nile virus in Ghana. *Viral Immunol.* 2009;22(1):17–22.
44. Lawson JMM, Mounguengui D, Ondounda M, et al. A case of meningoencephalitis due to West Nile virus in Libreville, Gabon. *Med Trop.* 2009;69(5):501–502.

45. Fall AG, Diaité A, Seck MT, et al. West Nile virus transmission in sentinel chickens and potential mosquito vectors, Senegal River Delta, 2008-2009. *Int J Environ Res Public Health.* 2013;10(10):4718–4727.

46. Venter M, Human S, Van Nickerk S, et al. Fatal neurologic disease and abortion in mare infected with lineage 1West Nile virus, South Africa. *Emerg Infect Dis.* 2011;17(8):1534–1536.

47. Faulde MK, Spiesberger M, Abbas B. Sentinel site enhanced near-real time surveillance documenting West Nile virus circulation in two Culex mosquito species indicating different transmission characteristics, Djibouti City, Djibouti. *J Egypt Soc Parasitol.* 2012;42(2):461–474.

48. Corwin A, Habib M, Olson J, et al. The prevalence of arboviral, rickettsial, and Hantaan-like viral antibody among school children in the Nile river delta of Egypt. *Trans R Soc Trop Med Hyg.* 1992;86(6):677–679.

49. Work TH, Hurlbut HS, Taylor RM. Indigenous wild birds of the Nile delta as potential West Nile virus circulating reservoirs. *Am J Trop Med Hyg.* 1955;4(5):872–888.